drugset / Trial / NCT04471818

Ketamine or Placebo in Patients With Major Depression and Advanced Cancer

NCT04471818

Phase 1/2 Completed 19 enrolled National Cancer Institute of Mexico
RandomizedParallel-groupDouble-blindTreatment

Summary

Major depression (MD) is a psychiatric disorder characterized by a persistent feeling of sadness, anhedonia or a decreased perception of pleasurable experiences, as well as appetite alterations and weight variations, sleep disorders, altered psychomotor skills, fatigue, guilt, decreased self-worth, suicidal thoughts and difficulty concentrating in a task (1). MD is a frequent complication in patients who are diagnosed with advanced cancer.

Timeline

Start
2019-09-19
Primary completion
2023-06-01
Completion
2023-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.5 mg/kg Intravenous